SDGR vs. TGTX, LNTH, NUVL, TLX, AXSM, ADMA, AKRO, PCVX, RYTM, and KRYS
Should you be buying Schrodinger stock or one of its competitors? The main competitors of Schrodinger include TG Therapeutics (TGTX), Lantheus (LNTH), Nuvalent (NUVL), Telix Pharmaceuticals (TLX), Axsome Therapeutics (AXSM), ADMA Biologics (ADMA), Akero Therapeutics (AKRO), Vaxcyte (PCVX), Rhythm Pharmaceuticals (RYTM), and Krystal Biotech (KRYS). These companies are all part of the "pharmaceutical products" industry.
Schrodinger vs. Its Competitors
TG Therapeutics (NASDAQ:TGTX) and Schrodinger (NASDAQ:SDGR) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk and dividends.
TG Therapeutics has a net margin of 10.13% compared to Schrodinger's net margin of -83.39%. TG Therapeutics' return on equity of 18.88% beat Schrodinger's return on equity.
58.6% of TG Therapeutics shares are held by institutional investors. Comparatively, 79.1% of Schrodinger shares are held by institutional investors. 10.6% of TG Therapeutics shares are held by insiders. Comparatively, 8.6% of Schrodinger shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
TG Therapeutics has a beta of 1.91, indicating that its stock price is 91% more volatile than the S&P 500. Comparatively, Schrodinger has a beta of 1.58, indicating that its stock price is 58% more volatile than the S&P 500.
TG Therapeutics presently has a consensus target price of $40.80, suggesting a potential upside of 14.57%. Schrodinger has a consensus target price of $33.25, suggesting a potential upside of 55.23%. Given Schrodinger's higher possible upside, analysts clearly believe Schrodinger is more favorable than TG Therapeutics.
TG Therapeutics has higher revenue and earnings than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, TG Therapeutics and TG Therapeutics both had 8 articles in the media. TG Therapeutics' average media sentiment score of 1.17 beat Schrodinger's score of 0.39 indicating that TG Therapeutics is being referred to more favorably in the media.
Summary
TG Therapeutics beats Schrodinger on 13 of the 15 factors compared between the two stocks.
Get Schrodinger News Delivered to You Automatically
Sign up to receive the latest news and ratings for SDGR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SDGR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Schrodinger Competitors List
Related Companies and Tools
This page (NASDAQ:SDGR) was last updated on 7/8/2025 by MarketBeat.com Staff
Free SDGR Stock Alerts